BPC-157: The 'Body Protection Compound' — Complete Research Review, Healing Protocols & Dosing

What Is BPC-157?

BPC-157 (Body Protection Compound-157) is a pentadecapeptide (15 amino acids) derived from a partial sequence of the human gastric protein BPC. Its amino acid sequence is: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val.

First isolated and characterized by Dr. Predrag Sikiric's research group at the University of Zagreb, BPC-157 has been continuously studied since the 1990s, primarily in rodent and in vitro models. Over 300 peer-reviewed papers document its effects across an extraordinary range of tissue systems.

It is currently in Phase 2 clinical trials for inflammatory bowel disease (PL14736) in an enteric form.

Mechanisms of Action

Angiogenesis Upregulation (VEGF / eNOS)

BPC-157's most well-documented mechanism is pro-angiogenic signaling — stimulating the formation of new blood vessels via VEGF (Vascular Endothelial Growth Factor) upregulation. This explains its remarkable healing effects on tendons, ligaments, bone, and muscle, which are all poorly vascularized tissues.

Nitric Oxide (NO) System Modulation

BPC-157 modulates the NO/eNOS system bidirectionally — reducing pathological NO in inflammatory states while restoring baseline NO signaling. This anti-inflammatory action without immune suppression distinguishes it from corticosteroids.

Growth Hormone Receptor Sensitization

Evidence suggests BPC-157 potentiates growth hormone receptor signaling — amplifying GH's tissue-repair effects without directly raising GH levels.

Serotonin / Dopamine Axis

BPC-157 modulates both serotonin and dopamine systems:

• •Upregulates dopamine receptors in the nucleus accumbens
• •Counteracts dopamine-depleting neurotoxins (research in amphetamine and alcohol models)
• •Shows antidepressant activity comparable to fluoxetine in some models

Gut-Brain Axis Protection

As a gastric protein derivative, BPC-157 has extraordinary GI-protective properties:

• •Protects against NSAID-induced gastric ulcers even at prophylactic doses
• •Heals inflammatory bowel lesions in Crohn's and colitis models
• •Modulates gut microbiome-brain signaling via vagal pathways

Research Evidence by Application

Tendon and Ligament Repair (Strongest Evidence)

• •Complete transection of Achilles tendon in rats: BPC-157 (10 μg/kg, IP) restored functional recovery 2× faster than controls
• •Biomechanical testing shows restored tensile strength and collagen organization
• •Human-equivalent extrapolation: estimated 500–1000 μg/day

Muscle Healing

• •Crushcutlass injury models: 40% faster functional recovery
• •Reduces satellite cell apoptosis; increases muscle progenitor cell proliferation

Gut Healing

• •Indomethacin-induced gastric ulcers: near-complete protection at 10 μg/kg
• •Colitis models: reduces mucosal inflammation, restores epithelial integrity
• •Short gut syndrome model: promotes bowel adaptation

Neurological Protection

• •TBI (traumatic brain injury) models: significantly reduced cognitive deficit, reduced edema
• •Stroke models: reduced infarct size, improved motor recovery
• •Peripheral nerve: regenerates crushed sciatic nerve faster than controls

Bone and Joint

• •Accelerates fracture healing and bone density restoration after corticosteroid-induced osteoporosis
• •Reduces joint inflammation in arthritis models

Dosing Protocols

Subcutaneous Injection (Highest Bioavailability)

• •Dose: 200–500 mcg once or twice daily
• •Inject near the injury site or in abdominal fat
• •Cycle: 6–8 weeks maximum; 4 weeks off minimum

Oral (Lower Bioavailability but Proven Effective for Gut)

• •Dose: 500–1000 mcg daily in split doses
• •Take on empty stomach with water
• •Most effective form for gut healing and systemic joint effects

Topical (Experimental)

• •200–500 mcg dissolved in saline applied to joint or wound area
• •Limited penetration but some supporting data

Stacking Protocols

Injury Repair Stack:

• •BPC-157: 250–500 mcg/day (SQ near injury)
• •TB-500 (Thymosin Beta-4): 2.5 mg 2× per week (systemic repair, actin cytoskeleton)
• •GHK-Cu topical peptide: Applied directly to injury site (collagen synthesis)
• •Vitamin C (liposomal): 2,000 mg/day (collagen cofactor)
• •Type II Collagen + UC-II: 40 mg/day (joint-specific)

Gut Healing Stack:

• •BPC-157 oral: 500 mcg 2× daily on empty stomach
• •Zinc carnosine: 75 mg 2× daily (potentiates gastric mucosa healing)
• •L-Glutamine: 5 g 2× daily (enterocyte fuel)
• •Saccharomyces boulardii (probiotic): 5B CFU/day
• •Slippery Elm: 400 mg before meals (mucosal coating)

Safety Profile

The safety profile of BPC-157 across animal models is exceptional:

• •No LD50 established in rodents even at very high doses
• •No observed mutagenicity, teratogenicity, or carcinogenicity in available studies
• •No immunosuppression (unlike steroids)

Human safety: No formal human safety trials published; Phase 2 trial data pending. The research community considers it low-risk based on animal evidence and widespread anecdotal usage. Use remains off-label.

Conclusion

BPC-157 represents one of the most promising peptides in regenerative medicine — with a breadth of tissue-healing effects that no single conventional pharmaceutical can match, and a safety profile that appears extraordinary in animal models. Until formal human trials complete, it remains a research compound, but its mechanisms are sound, its animal evidence is extensive, and its anecdotal human usage database is substantial.